|1.||Peltonen, Juha: 2 articles (08/2007 - 08/2004)|
|2.||Aaltonen, Vesa: 2 articles (08/2007 - 08/2004)|
|3.||Laato, Matti: 2 articles (08/2007 - 08/2004)|
|4.||Koivunen, Jussi: 2 articles (08/2007 - 08/2004)|
|5.||Biswas, D K: 2 articles (08/2001 - 07/2000)|
|6.||Pardee, A B: 2 articles (08/2001 - 07/2000)|
|7.||Yi, Bo: 1 article (09/2015)|
|8.||Chen, Changyan: 1 article (09/2015)|
|9.||Peng, Bo: 1 article (09/2015)|
|10.||Huang, Junchi: 1 article (09/2015)|
08/15/2004 - "Go6976 was also highly effective in inhibiting migration of carcinoma cells and inhibited invasion through artificial basement membrane. "
10/01/2010 - "T24 urinary bladder carcinoma cells, known to express hyperphosphorylated Rb, were treated with PKCα/βI inhibitor Go6976. "
08/15/2004 - "Our results on urinary bladder carcinoma cells emphasize that Go6976 is a potential anticancer drug due to its effects on cell-cell and cell-matrix junctions, migration, and invasion. "
08/15/2004 - "Exposure of the cells to isoenzyme-specific PKC inhibitors yielded variable results: Go6976, an inhibitor of PKCalpha and PKCbeta isoenzymes, induced rapid clustering of cultured carcinoma cells and formation of an increased number of desmosomes and adherens junctions. "
08/15/2004 - "Protein kinase C alpha/beta inhibitor Go6976 promotes formation of cell junctions and inhibits invasion of urinary bladder carcinoma cells."
03/01/2005 - "Furthermore, kinetic studies and analysis of HIV-1 products indicated that alpha-defensin-1 and Go6976 blocked HIV-1 infection at similar stages in its life cycle, including nuclear import and transcription. "
03/01/2005 - "Like alpha-defensin-1, the PKC isoform-selective inhibitor Go6976 blocked HIV-1 infection in a dose-dependent manner. "
|3.||Transitional Cell Carcinoma
10/01/2010 - "The results show that Go6976 can be used to restore constantly hyperphosphorylated and therefore constantly inactive Rb function in cancer cells."
08/08/2007 - "Importantly, the results demonstrated that both doxorubicin treated and non-synchronized cancer cells are forced to mitosis by Go6976. "
08/28/2001 - "(i) Local administration of Go6976 an inhibitor of protein kinases C alpha and beta inhibited growth of tumors and caused extensive necrotic degeneration and regression of the tumors without causing any microscopically detectable damage to the vital organs liver and lung. "
07/01/2001 - "With the use of PKC alpha--specific inhibitors (safingol, Go6976) as well as the PKC delta--specific inhibitor rottlerin, we showed that only PKC alpha plays a major role in the regulation of tumor cell migration. "
01/15/2003 - "Both the protein kinase C (alpha/beta) inhibitor Go6976 and expression of dominant-negative nuclear factor (NF)-kappaB inhibitor kinase mutants: (a) blocked the growth and caused regression of a mammary tumor insyngeneic mice; (b) inhibited epidermal growth factor (EGF)-induced activation, nuclear translocation, and DNA-binding activity of NF-kappaB; and (c) caused apoptosis of EGF-stimulated cultured mammary tumor cells. "
01/01/2014 - "Taken together these findings suggest that Go-6976 exerts its effect in alleviating hyperglycemia-induced insulin-resistance independently of cPKC inhibition and may target components of the mTORC1 signaling pathway. "
01/01/2014 - "Here, we demonstrate that treatment with Go-6976, a widely used "specific" inhibitor of cPKCs, alleviates hyperglycemia-induced insulin resistance. "
01/01/2014 - "Go-6976 reverses hyperglycemia-induced insulin resistance independently of cPKC inhibition in adipocytes."
03/01/2001 - "Preincubation with Go6976, LY379196 or myristoylated PKC pseudosubstrate, conventional PKC inhibitor, but not cycloheximide or RU38486, recovered dexamethasone-induced insulin resistance. "
|2.||Protein Kinase C-alpha
|3.||Protein Isoforms (Isoforms)
|4.||NF-kappa B (NF-kB)
|6.||Proteasome Endopeptidase Complex (Proteasome)
|10.||Cell Adhesion Molecules